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Repair
SocietyThere have been numerous recent publications reporting an
association of pseudoseptic reactions, or severe acute
inﬂammatory reactions (SAIRs), with the use of hylan G-F
20 injections (Synvisc, Genzyme Biosurgery, Cambridge,
MA) as treatment for pain associated with osteoarthritis
(OA) of the knee. These have recently been reviewed, and
an additional four reports have appeared since that
review1e5. The reactions are characterized clinically by 1)
severe joint inﬂammation, 2) a typical requirement for more
than one injection (e.g., after a second or third injection in
a course or after initiation of a repeat treatment course), 3)
the absence of infectious agents or calcium pyrophosphate
crystals associated with sepsis or pseudogout, 4) high
numbers of inﬁltrating mononuclear cells in the synovial
ﬂuid, and 5) the requirement for clinical intervention (e.g.,
arthrocentesis, intra-articular steroid injection, and/or non-
steroidal anti-inﬂammatory drugs)1. To date, although there
has been one report in the literature from a non-crosslinked
fermented hyaluronan product6, there have been no
published accounts of these reactions occurring in patients
receiving the avian-derived, naturally extracted sodium
hyaluronate products approved in the US. Because the
pseudoseptic reactions share characteristics with immune
sensitization, it has been suggested that there may be a link
between the pseudoseptic reactions and the chemical
crosslinking process used to increase molecular weight
(MW) during the manufacture of hylan G-F 20; this process
is not used during the manufacture of currently marketed
sodium hyaluronates7,8. We previously reported that seven
subcutaneous immunizations of rabbits with hylan, but not
sodium hyaluronate (MW 500e730 kDa, Hyalgan, Fidia
SpA, Padua, Italy), induced antibodies, as measured by
enzyme-linked immunosorbent assay (ELISA), to the
chicken proteins found abundantly in the source material
for hyaluronan products. Rabbits immunized with a crude
rooster comb preparation (CRC) were a positive control in
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2004.2the study9. Sasaki et al.10 more recently reported that
injections of animals with hylan, but not sodium hyaluronate
(MW 620e1160 kDa, Supartz or MW 500e730 kDa),
induced speciﬁc antibody responses and granulomatous
reactions, which may be related to the clinical reports of
chronic granulomatous reactions in patients receiving hylan
G-F 2011. Similar results have again recently been reported
in guinea pigs and mice12 and, in addition, animal data from
Schiavinato et al.13 suggest that a fulminant inﬂammatory
reaction in the knee joint frequently occurs in response to
hylan G-F 20 and not sodium hyaluronate after prior
exposure to 1e2 intra-articular injections. Collectively,
these studies suggest that these reactions may result from
immune sensitization to a component of hylan that is not
present in sodium hyaluronate preparations. The present
study has extended previous ﬁndings by biochemically
identifying a potential immunogenic protein present in hylan
G-F 20 but not sodium hyaluronate (MW 500e730 kDa) that
may serve as the target for the observed acute inﬂamma-
tory reactions to hylan G-F 20.
A hyaluronidase-digested CRC preparation (undigested
CRC ran as a smear) was separated on 4e20% sodium
dodecyl polyacrylamide gel electrophoresis (SDS-PAGE)
gels and blotted to nitrocellulose. Western blots of a CRC
extract were then performed using the rabbit antisera from
rabbits immunized with various sources of hyaluronans as
previously described9,14. Bovine serum albumin-blocked
blots were incubated with 1:500 dilutions of terminal bleed
pools from each of the three groups of rabbits immunized
with CRC, hylan G-F 20, or sodium hyaluronate (MW
500e730 kDa), respectively9. A quantitative ELISA using
the same source of hyaluronidase-digested CRC prepara-
tion to coat ELISA plates was done to titrate the various lots
of antisera (shown in Fig. 1). Immunoblots were then
washed and developed using goat anti-rabbit horseradish
peroxidase (1:2500) (KPL, Catalog #074-1516) followed by
tetramethyl benzidine (TMB) substrate (KPL, Catalog #50-
77-03). As shown in Fig. 2, anti-CRC antisera recognized
multiple bands, but predominantly a 6- to 8-kDa protein
band. Reactivity with a similarly migrating chicken protein
band of 6 to 8 kDa was also seen with antisera from
hylan-immunized rabbits. However, the sera from rabbits
injected with sodium hyaluronate (MW 500e730 kDa) had
no reactivity with any band.66
267Osteoarthritis and Cartilage Vol. 13, No. 3Several lines of clinical evidence have implicated an
immunologic basis for SAIRs. For example, reactions tend
to require prior exposure or ‘sensitization’ and, in one
clinical study, the incidence of SAIRs increased 10-fold
with repeat vs single courses of hylan15. Additionally,
Puttick et al.16 found chicken-protein-reactive antibodies in
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Fig. 1. Antibody titers from sera of rabbits immunized with various
hyaluronan products used in Western blots. Rabbits were
immunized with respective products a total of 7 times with
approximately 2 mg of hyaluronan equivalents (CRC, Crude
Rooster Comb preparation; SYN, Synvisc; HYL, Hyalgan), without
adjuvant, over a 5-month period. Sera samples were collected at 6
months and individual rabbits, CRC Rabbit 7458, SYN Rabbit 7462,
HYL Rabbit 7466, or pools of SYN immunized rabbits, High Titer
Pool, Medium Titer Pool, and a Low Titer Pool, were analyzed at
various concentrations. All samples were added to chicken protein
coated, blocked and washed plates, and incubated for 1 h at 25(C.
Detection of rabbit antisera occurred using goat anti-rabbit-HRP at
1:5000 in 1! PBSC Tween for 1 h, 25(C followed by TMB
substrate for 10 min. The substrate reaction was stopped with 2 N
H2SO4 and read at 450 nm. The High Titer Pool was used to detect
protein bands in the Western blots for Synvisc.serum from a patient with a SAIR. Several investigators
have reported ﬁnding immune cell inﬁltrates in synovial
ﬂuid of patients despite the absence of infection, and
bilateral reactions have been seen, suggesting in some
cases there may be systemic involvement1. It has also
been recently reported that patients who experienced
a SAIR following injections with hylan G-F 20 could be
subsequently treated with sodium hyaluronate (MW
500e730 kDa) injections, with no further adverse re-
action4,17; this further supports the possible immunologic
speciﬁcity of the reaction to hylan.
The results of this preclinical study conﬁrm the presence
of a speciﬁc immunogenic protein species in hylan G-F 20
preparation but not sodium hyaluronate (MW 500e
730 kDa), and suggest that an immune reaction to a 6-
to 8-kDa protein within a CRC preparation contributes to
this immunogenicity. It is possible that this protein is
present in the natural hyaluronan source and mildly
immunogenic. However, the concentration of the protein
in the CRC that elicited this antibody response vs that
possibly present in either of the ﬁnished hyaluronan
products is likely to be substantially greater. It is unlikely
that this protein, in the concentrations present in ﬁnished
products, is itself highly immunogenic, as immunization
with the naturally extracted sodium hyaluronate failed to
elicit an antibody response. We consider it more likely that
a derivatized, more immunogenic variant of this protein,
resulting from the aldehyde crosslinking in the hylan
manufacturing process, is the primary candidate. Indeed,
we suggest that this component may play a role in the
induction of an immunological reaction that may lead to
SAIRs or the chronic granulomatous reactions that have
been associated with repeated hylan injections11. Our
current work is aimed at determining whether antibodies
reactive with the 6-kDa protein species are present in
the synovial ﬂuid and sera from patients who have
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Fig. 2. Silver stain and Western blots of hyaluronidase-digested Crude Rooster Comb (CRC) (50, 12.5, and 7.5 mL per lane). Detection with
anti-CRC rabbit sera blot shows reactivity with multiple bands in the 48- to 56-kDa region and a predominant diffuse band at 6- to 8-kDa
protein. Reactivity with a 6- to 8-kDa protein is also observed almost exclusively with the anti-hylan G-F 20 rabbit sera blot. There is no
reactivity observed in the anti-sodium hyaluronate rabbit sera blot.
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